Valeant to buy private dental company for $312 million

Canadian drugmaker Valeant Pharmaceuticals International Inc will buy privately held drugmaker OraPharma for about $312 million, to enter the dental market.

The company, which has been on a buying spree across various geographies since Michael Pearson took over as its chief executive four years ago, said it will also pay $114 million in potential contingent payments based on certain milestones.

The deal, which is expected to close in June, will add to Valeant’s earnings in 2012, the company said in a statement.

OraPharma is owned by private equity firm Water Street Healthcare Partners.

The company makes Arestin, a locally administered antibiotic for the treatment of periodontitis - an infection of the ligaments and bones that support the teeth.

As of March 31, OraPharma’s twelve month net revenue was about $95 million.

(Reporting by Aftab Ahmed in Bangalore; Editing by Supriya Kurane)

###

(Reuters)

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

Sex and violence may not really sell products   GPs and the Fit for Work scheme   Study shows global warming is unlikely to reduce winter deaths   Academies make recommendations for improving public health   As death rates drop, nonfatal diseases and injuries take a bigger toll on health globally   Designing better medical implants   Single low-magnitude electric pulse successfully fights inflammation   Total annual hospital costs could be reduced by rapid candidemia identification   UTMB develops new online tool for nurses   Online health information - keep it simple!   Your privacy online: Health information at serious risk of abuse   Physician guidelines for Googling patients need revisions